Mean change from baseline for perceived cognitive impairments (A), cognitive functioning (B), usual level of fatigue (C) and fatigue interference (D) at.

Slides:

Advertisements

Similar presentations

A Survey of Quality of Life Following Surgery for Malignant Pleural Mesothelioma: Reflects the patients’ commitment to Learning about the Disease D A Raffle,

Advertisements

Date of download: 9/20/2016 From: Massage Therapy versus Simple Touch to Improve Pain and Mood in Patients with Advanced Cancer: A Randomized Trial Ann.

Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

LUX-Lung 3 clinical trial

An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With.

Stephanie J. Lee, Loretta A. Williams

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

A Multitargeted Treatment Approach for Anemia and Cachexia in Metastatic Castration- Resistant Prostate Cancer Antonio Macciò, MD Journal of Pain and.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera.

Quality-of-life scores in neurogenic thoracic outlet syndrome patients undergoing first rib resection and scalenectomy Danielle H. Rochlin, BA, Marta.

Volume 54, Issue 2, Pages (August 2008)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Capture, Transfer, and Feedback of Patient-Centered Outcomes Data in Palliative Care Populations: Does It Make a Difference? A Systematic Review Simon.

Evaluating Cognitive, Emotional, and Physical Fatigue Domains in Daily Practice by Single-Item Questions in Patients With Advanced Cancer: A Cross-Sectional.

Bar charts comparing the results of ePROMs between patients who found the scores inadequately assessed their symptoms against all other patients leaving.

Stacy D. Sanford, PhD, Jennifer L

Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France Nicolas Despiégel, Chantal Touboul, Alain.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Stephanie J. Lee, Loretta A. Williams

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Flow chart of the used methodology adapted from Moher et al

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves for overall survival (OS) probability.

Konstantinos C. Siontis et al. JACEP 2016;2:

Methods distribution among the three EQAs

Patients represented by 441 physicians surveyed from 19 countries, depicted in the patient journey from diagnosis to ensuing treatment with ADT. ADT, androgen.

Mean difference between treatment groups in the change from baseline for all PRO scores at months 1, 2 and 3. *Evaluable patients. Mean difference between.

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

An inflammatory triple negative breast cancer of an African woman before (A) and after (B) treatment. An inflammatory triple negative breast cancer of.

Mean change from baseline in symptom scales and single-item assessments after 6 weeks of alectinib treatment according to (A) the QLQ-C30 and (B) the QLQ-LC13.

Richard J Gralla, MD, Frank Griesinger, MD, PhD

Awareness of respondents about the availability or development of specialised services for AYA where adult and paediatric cancer specialists work together.

Tumour types of patients whose cancers harboured actionable molecular alterations in our series. ACUP, adenocarcinoma with unknown primary. Other: appendix.

Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.

Change in individual tolerability assessment between baseline and study completion. Change in individual tolerability assessment between baseline and study.

Gender representation of board members in all international societies (reference year: 2016). Gender representation of board members in all international.

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Gender representation in all international congresses (reference year 2016). Gender representation in all international congresses (reference year 2016).

Physical Function in Patients with Cancer

Concentration-time profiles of repeated weekly infusions of (A) 720 mg and (B) 990 mg tomuzotuximab measured in individual patients before and at the end.

Percentages of patients reporting improvements from baseline ≥minimum clinically important difference (MCID) and number needed to treat (NNT) in (A) patient-reported.

Health-related quality of life (HRQOL) results.

Proportion of continuous, intermittent, and limited (

Least squares mean changes from baseline (and 95% CIs) at month three for (A) HAQ-DI, (B) FACIT-F and (C) SF-36 physical functioning domain observed in.

Overview of cancer genetics in the SMP1 cohort: lung cancer (A), breast cancer (B), colorectal adenocarcinoma (except mucinous subtype) (C), prostate cancer.

(A) The stratified analysis for DFS because of the uncertain status of HER2, 132 patients could be calculated the recurrence risk score. (A) The stratified.

Proportion of patients reporting improvements from baseline in patient-reported outcomes (PROs) ≥ the MCID at (A) 16 weeks in OPTION, (B) 12 weeks in BREVACTA.

The 22 study patients: overall survival (first patient enrolled 9 May 2014, last patient enrolled 26 August 2015, censoring date 9 May 2016); primary tumour.

(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of

Kaplan-Meier plot of overall survival from the time of first dose of intrathecal interleukin-2 (IT IL-2) for all patients (A, n=43) and based on the extent.

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Kaplan-Meier plots of (A) time to first improvement and (B) time to first deterioration in pain in the chest, cough and dyspnoea, according to the 13-Item Quality.

Heterogeneity in the natural history of triple negative breast cancer.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Clinically meaningful worsening (versus improvement or no change)

Prescribers’ responses rating their level of comfort on a scale of 1–5

(A) Short Health Scale (SHS) dimension scores (left) and Psychological General Well-Being Index (PGWBI) global scores (right) for the open-label phase.

Meta-analysis of the effect of gender in the overall survival, comparing HRs and 95% CI obtained from multivariate analysis in hospital databases. Meta-analysis.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

Mean change from baseline for perceived cognitive impairments (A), cognitive functioning (B), usual level of fatigue (C) and fatigue interference (D) at months 1, 2 and 3. For FACT-Cog higher scores are favourable; for EORTC QLQ-C30 functional scales and global health status/QoL higher scores are favourable, for EORTC QLQ-C30 symptom scales lower scores are favourable; for BPI-SF and BPI-SF lower scores are favourable AAP, abiraterone acetate plus prednisone; BFI-SF, Brief Fatigue Inventory-Short Form; BPI-SF, Brief Pain Inventory-Short Form; CI, confidence interval; ENZ, enzalutamide; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life questionnaire; FACT-Cog, Functional Assessment of Cancer Therapy -Cognitive Function; PRO, patient-reported outcome. Mean change from baseline for perceived cognitive impairments (A), cognitive functioning (B), usual level of fatigue (C) and fatigue interference (D) at months 1, 2 and 3. For FACT-Cog higher scores are favourable; for EORTC QLQ-C30 functional scales and global health status/QoL higher scores are favourable, for EORTC QLQ-C30 symptom scales lower scores are favourable; for BPI-SF and BPI-SF lower scores are favourable AAP, abiraterone acetate plus prednisone; BFI-SF, Brief Fatigue Inventory-Short Form; BPI-SF, Brief Pain Inventory-Short Form; CI, confidence interval; ENZ, enzalutamide; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life questionnaire; FACT-Cog, Functional Assessment of Cancer Therapy -Cognitive Function; PRO, patient-reported outcome. Antoine Thiery-Vuillemin et al. ESMO Open 2018;3:e000397 Copyright © European Society for Medical Oncology. All rights reserved.